GTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement CHICAGO, May
Genomic Testing Cooperative and its founder and CEO, Dr. Maher Albitar, were recently featured in the Houston Business Journal in a “Face to Face” profile highlighting
New central U.S. location strengthens testing capacity and turnaround times while positioning GTC within the Texas Medical Center ecosystem HOUSTON — March 12, 2026 — Genomic
Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for
Summit Health Announces Internalization of GTC’s State-of-The-Art Next Gen Sequencing DNA & RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic
GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025 Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with
Lake Forest, CA – April 8, 2025 – Genomic Testing Cooperative (GTC) today announced it received UKCA marks for its Hematology Profile Plus, Solid Tumor
Cologne, Germany and Lake Forest, CA. USA, March 18, 2025 – Labor Dr. Wisplinghoff one of Germanys largest and most renowned medical laboratories and Genomic
Lake Forest, CA – November 13, 2024 – Genomic Testing Cooperative (GTC), a leader in advanced genomic testing, announced the launch of GTC Interpret, a
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
